Pull to refresh
Logo
KKR agrees to take medtech supplier Integer Holdings private

KKR agrees to take medtech supplier Integer Holdings private

Money Moves

A $5.7 billion all-cash deal pulls a major maker of heart- and nerve-device parts off public markets.

August 3rd, 2026: KKR agrees to buy Integer for $5.7 billion

Overview

Updated Aug 8

Integer Holdings builds the parts that go inside pacemakers, defibrillators, and nerve-stimulation devices. On August 3, the private-equity firm KKR agreed to buy the whole company for about $5.7 billion and pull it off the public market.

Integer is one of the largest contract manufacturers in medical technology, supplying Abbott, Boston Scientific, and Medtronic. Shareholders get $127 a share in cash, a 52% premium to the price before the company put itself up for review. If the deal closes by year-end, a critical supplier leaves public markets and moves under private ownership.

Why it matters

A company that makes parts inside heart and nerve devices for Abbott, Boston Scientific, and Medtronic will now answer to private-equity owners.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

0

What do private equity owners usually do once they take controll?

PE owners load the company with acquisition debt, squeeze out costs and margin over 3-7 years, then sell or IPO it — a playbook that's paid off for KKR in most deals but blew up spectacularly with its 2018 Envision Healthcare buyout.

Why it matters: Integer supplies parts for pacemakers and defibrillators to Abbott, Boston Scientific and Medtronic, so how KKR manages debt and cost pressure at the company could ripple through the medical-device supply chain those makers depend on.

  • Leveraged buyouts typically put down a fraction of the purchase price in equity and finance the rest with debt secured against the target's own assets and cash flow — the company, not the PE firm, carries the debt burden.
  • Owners then push operational improvements and cost-cutting (layoffs, restructuring, asset sales) to boost margins and service that debt, aiming to grow enterprise value before an exit.
  • Holding periods now average around 7 years, with exits via strategic sale, resale to another PE firm, or an eventual IPO.
  • KKR's own record shows the risk: its $10 billion Envision Healthcare buyout used $5 billion in debt and collapsed into Chapter 11 in 2023 when COVID-era volume drops and reimbursement changes left the company unable to service that debt, wiping out KKR's roughly $3.5 billion equity stake.
Room for disagreement
  • PE industry defenders argue cost discipline and leverage genuinely improve operational efficiency and can grow a company faster than public-market ownership allows.
  • Critics like the Private Equity Stakeholder Project point to cases like Envision as evidence that heavy debt loads regularly push portfolio companies into distress or bankruptcy, especially in healthcare where regulatory and reimbursement shifts can hit cash flow hard.
AI-generated with web search — may be wrong. Check the linked sources.

Key Indicators

$5.7B
Enterprise value
Total value of the all-cash deal, including debt.
$127
Price per share
Cash paid for each Integer share.
52%
Premium
Over the share price the day before Integer's strategic review.
$796B
KKR assets
KKR's assets under management at the end of the second quarter of 2026.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

People Involved

Organizations Involved

Timeline

May 2023 August 2026

4 events Latest: August 3rd, 2026 · 1 month ago
Tap a bar to jump to that date
  1. KKR agrees to buy Integer for $5.7 billion

    Latest M&A

    KKR will pay $127 a share in cash, a 52% premium to Integer's price before the review. The deal is set to close by the end of 2026.

  2. Integer opens a strategic review

    Corporate

    The company announces a review to weigh its options after what it calls strong interest. The move puts Integer in play.

  3. Payman Khales takes over as CEO

    Leadership

    Khales, the company's first chief operating officer, replaces the retiring Joseph Dziedzic and joins the board.

  4. KKR's Envision Healthcare files for bankruptcy

    Context

    KKR's $9.9 billion healthcare buyout collapses into Chapter 11, costing the firm about $5 billion. It frames the risk in KKR's healthcare deals.

Scenarios

1

KKR completes the Integer buyout and shares delist

Likely Resolves by Q1 2027

Discussed by: Integer and KKR guidance; MedTech Dive

Shareholders approve the $127-a-share price, a rich premium that gives them little reason to object. Regulators clear the deal. Integer stops trading on the New York Stock Exchange and becomes a KKR-owned company. This is the base case both sides describe.

2

A rival bidder tops KKR's $127 offer

Unlikely Resolves by End of 2026

Discussed by: M&A analysts tracking Integer's proxy filings

The strategic review drew strong interest, and a strategic buyer or another private-equity firm could come back with more. If a superior proposal surfaces before the shareholder vote, Integer's board could switch partners or push KKR to raise its price. No competing bid has been made public so far.

3

The deal is terminated before closing

Unlikely Resolves by Q1 2027

Discussed by: Deal lawyers reviewing regulatory and financing risk

A regulatory objection, a financing problem, or a material adverse change could break the agreement. Antitrust review of a supplier that sells to competing device makers is one possible snag. Nothing so far points to a block, but the deal must clear customary conditions before it closes.

4

KKR bolts a new acquisition onto Integer within a year of closing

Possible Resolves by End of 2027

Discussed by: KeyBanc Capital Markets analyst Brett Fishbin

Fishbin expects KKR to treat Integer as a platform and add smaller manufacturers to it. Away from quarterly earnings pressure, KKR can fund purchases and fold them into Integer's operations. A first bolt-on deal within a year of closing would confirm that strategy.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

June 2018 - May 2023

KKR buys Envision Healthcare (2018-2023)

KKR bought physician-staffing company Envision Healthcare in 2018 for $9.9 billion, including debt. Envision staffed emergency rooms and billed patients directly. A 2020 federal law against surprise medical bills gutted that model.

Then

Envision filed for Chapter 11 bankruptcy in May 2023 with roughly $7 billion in debt. Lenders took over the assets.

Now

KKR lost about $5 billion, one of its biggest healthcare failures.

Why this matters now

Integer is a healthcare bet too, but a different kind. It sells parts to device makers instead of billing patients, so it avoids the payment-reform risk that sank Envision.

June 2021

Medline leveraged buyout (2021)

Blackstone, Carlyle, and Hellman & Friedman bought medical-supply maker Medline in a deal worth about $34 billion including debt. It was the largest healthcare buyout in years.

Then

Medline stayed private and kept supplying hospitals with gloves, gowns, and other basics.

Now

The deal showed how far private equity had moved into the medical supply chain.

Why this matters now

Integer, like Medline, is a supplier rather than a brand patients recognize. The buyout continues private equity's push into the plumbing of healthcare.

February-December 2024

Novo Holdings buys Catalent (2024)

Novo Holdings agreed to buy Catalent, a contract manufacturer for drugmakers, for $16.5 billion. The deal took a critical supplier private and closed in December 2024.

Then

Catalent left public markets and became a private supplier feeding the pharma industry, including Novo's own weight-loss drugs.

Now

It showed strong buyer appetite for the outsourced manufacturers that big drug and device companies depend on.

Why this matters now

Like Catalent, Integer is a behind-the-scenes maker that others rely on. Both deals pull that kind of supplier off public markets and under a single owner.

Sources

(6)